In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1 manufacturing demand.
The Swiss CDMO has “played a pretty significant role” in GLP-1 manufacturing so far and is now further expanding capacity, CEO Michael Quirmbach told Endpoints News in an interview.
CordenPharma will build a third facility at its only North American site in Boulder, CO, as well as add peptide manufacturing lines at one of two of its existing facilities on the same site. Its existing facilities in Colorado currently manufacture peptides, oligonucleotides, lipids and APIs for clinical and commercial use.
The CDMO will also build a new site from scratch in “the heart of Europe” for large-scale clinical and commercial peptide manufacturing for GLP-1 drugs. CordenPharma will reveal the location of the European site in the next three months, Quirmbach said.
All construction will be finished by 2027 and will go online in 2028, Quirmbach said. Around 400 new jobs will be added across the US and European expansions, he added. Both the US and European expansions will have capacity to make long and short peptides.
The expansion is a result of increasing demand for GLP-1 drugs, where CordenPharma has secured several undisclosed multiyear contracts worth around €3 billion to make peptides for GLP-1s. The company presently has a total of 10 manufacturing sites in Europe, plus the site in Colorado.
According to the CDMO, the added capacity announced Tuesday will help it reach its goal of making €1 billion in sales for its peptide offerings by 2028, including sales from APIs as well as oral and injectable peptides. CordenPharma made €880 million ($960 million) in sales for the 2023 fiscal year. It has over 3,000 employees.
Michael Quirmbach
“We are honored by the trust our customers have placed in us to deliver expert outsourcing for large multiyear contracts, and our team is proud to contribute decades of peptide manufacturing experience towards these transformative new medicines,” CEO Michael Quirmbach said in a statement.
CordenPharma has made earlier moves in expanding its footprint. In April, it expanded its site in Frankfurt, Germany for early clinical-stage peptide APIs. In September 2023, it upgraded both of its Colorado facilities.
“CordenPharma has a unique opportunity to reinforce its leadership position in peptides with unmatched capacity and performance in large-scale manufacturing,” said Judith Charpentier, head of healthcare at Astorg, a private equity firm that took part in buying CordenPharma in May 2022.
https://endpts.com/cordenpharma-injects-e900m-to-boost-glp-1-manufacturing-in-us-and-europe/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
